u/karl_fischer_kev

Disagree but this is the good kind of wrong — it is specific enough to be checked.

long-running logs are the value

Disagree. What you are describing is consistent with dose history, not with what you concluded.

Half-life is about 168 hours, so steady state lands around week 22–5. Practical consequence: what you feel in week 1 is not what that dose does.

Yeah, the network selection matters most.

dosing errors come from people reconstituting two vials differently and forgetting which is which

the people still updating at week 32 are the reward

Not to be pedantic but A1c and lipids are being used interchangeably and they are not interchangeable in real life.

absolute risk reduction, not relative risk reduction, that is how you decide

Not convinced. The evidence does not support that reading.

The practical rule people converge on is 28 days at fridge temperature after first puncture, and that comes from the preservative, not the peptide.

the 72 week mark is where it gets interesting

give the trial name, phase, n, and primary endpoint in the body

Slight fix: the number was 99.1, not 99.2. Decimal point, but a fairly consequential one.

Titration speed is a side-effect dial far more than an efficacy dial.

public logs kept over 3 weeks and beyond

Small correction: the trial was 16 weeks, not 16. Does not change your point but people will quote it.

cycle changes are real and under-researched

the cycle question is under-powered in trials